USFDA completes inspection of Strides Pharma Bengaluru plant
Team Udayavani, Jul 20, 2019, 6:13 PM IST
Image for Representation
Bengaluru: Drug firm Strides Pharma Science said on Saturday the inspection of its formulation facility in Bengaluru by the US health regulator has completed successfully with a voluntary action indicated (VAI) classification.
The company’s facility in Bengaluru underwent a United States Food and Drug Administration (USFDA) inspection that ended on May 24, 2019, Strides Pharma Science said in a statement.
The Bengaluru facility is the largest manufacturing facility for the company with capabilities to produce finished dosage formulation products across multiple dosage formats including tablet, capsules, ointments, creams and liquids, Strides Pharma said.
The facility services key regulated markets of the US, Europe, and Australia, it added.
Udayavani is now on Telegram. Click here to join our channel and stay updated with the latest news.
Top News
Related Articles More
All-woman COVID-19 vaccine booth launched in Karnataka
New mineral policy for 2021-26 on the anvil says CM BSY
Don”t call me Yediyurappa,if I don”t make you sit in oppn forever: Karnataka CM on Cong walkout during budget
Rs 7,795 cr for development of B’luru; action towards Mekedatu Balancing Reservoir: CM
Karnataka budget people friendly as no new taxes or new tax proposals: Yediyurappa
MUST WATCH
Latest Additions
Kerala industrial charity outfit-turned-political party to contest from five assembly seats
Govt to amend telecom licence norms to control sourcing from China, non-friendly destinations
Serum Institute seeks govt’s intervention over import of COVID vaccine raw material from US
All-woman COVID-19 vaccine booth launched in Karnataka
New mineral policy for 2021-26 on the anvil says CM BSY